Zacopride, an IK1 agonist with moderate potency, could exert significant antiarrhythmic and cardiac protective effects. To date, there is no report to show that zacopride is proarrhythmic in both experimental studies and clinical trials. However, in certain cardiac pathological conditions, especially short QT syndrome and certain reentry tachycardia, zacopride is not suggested. Further studies are needed to precisely evaluate the potential arrhythmogenic risk of zacopride.

Zacopride shows potential antiarrhythmic and cardiac protective effects without a proarrhythmic risk in most cases, but may not be suitable for short QT syndrome and certain reentry tachycardia.

Paper

On the risk concerns of zacopride, a moderate IK1 channel agonist with cardiac protective action.

References

Citations